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Abstract
Abnormal tau phosphorylation (p-tau) has been shown after hypoxic damage to the brain associated with traumatic brain injury
and stroke. As the level of p-tau is controlled by Glycogen Synthase Kinase (GSK)-3b, Protein Phosphatase 2A (PP2A) and Ade-
nosine Monophosphate Kinase (AMPK), different activity levels of these enzymes could be involved in tau phosphorylation follow-
ing ischaemia. This study assessed the effects of global brain ischaemia/reperfusion on the immediate status of p-tau in a rat
model of cardiac arrest (CA) followed by cardiopulmonary resuscitation (CPR). We reported an early dephosphorylation of tau at
its AMPK sensitive residues, Ser396 and Ser262after 2 min of ischaemia, which did not recover during the first two hours of reper-
fusion, while the tau phosphorylation at GSK-3b sensitive but AMPK insensitive residues, Ser202/Thr205 (AT8), as well as the total
amount of tau remained unchanged. Our data showed no alteration in the activities of GSK-3b and PP2A during similar episodes
of ischaemia of up to 8 min and reperfusion of up to 2 h, and 4 weeks recovery. Dephosphorylation of AMPK followed the same
pattern as tau dephosphorylation during ischaemia/reperfusion. Catalase, another AMPK downstream substrate also showed a
similar pattern of decline to p-AMPK, in ischaemic/reperfusion groups. This suggests the involvement of AMPK in changing the p-
tau levels, indicating that tau dephosphorylation following ischaemia is not dependent on GSK-3b or PP2A activity, but is associ-
ated with AMPK dephosphorylation. We propose that a reduction in AMPK activity is a possible early mechanism responsible for
tau dephosphorylation.
Introduction
Cognitive and memory impairment following stroke and cardiac
arrest (CA) have been reported (Tatemichi et al., 1992; Pohjasvaara
et al., 1998; Madureira et al., 2001; Mateen et al., 2011). Reperfu-
sion after ischaemia is thought to precipitate neurodegenerative
events such as beta amyloid (Ab) accumulation and the over-expres-
sion of phosphorylated tau (p-tau) in the hippocampus (Geddes
et al., 1994) and cortex (Dewar & Dawson, 1995).
Hyperphosphorylated tau has been associated with ischaemic
insults (Mailliot et al., 2000; Castro-Alvarez et al., 2011), and is
responsible for its loss of biological activity, and neuroﬁbrillary
degeneration in Alzheimer’s disease (AD) (Iqbal et al., 1998), where
paired helical ﬁlaments and neuroﬁbrillary tangles (NFTs), are hall-
marks of AD brain lesions (Ballatore et al., 2007; Noble et al.,
2011).
Glycogen Synthase Kinase-3 (GSK-3b) and Protein Phosphatase
2A (PP2A) are thought to control the levels of tau phosphorylation
(Spittaels et al., 2000; Eldar-Finkelman, 2002; Liu et al., 2005a).
GSK-3b is linked to tangle-bearing neurons (Pei et al., 1999; Lovell
et al., 2004), and phosphorylates tau in about 40 residues; however
there are some residues insensitive to its action (Guerra-Araiza
et al., 2007; Hanger et al., 2007; Hanger & Noble, 2011). GSK-3b
could be inﬂuenced by ischaemia, 5 min of brain ischaemia
increased GSK-3b phosphorylation at Ser9 and decreased its activity
(Brywe et al., 2005; Endo et al., 2006). Increased phosphorylation
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of Ser9 in GSK-3b has also been reported following traumatic brain
injury (Brywe et al., 2005).
Protein Phosphatase 2A reduces p-tau and works in balance with
GSK-3b (Liu et al., 2005a). Phosphorylation at Tyr307 or down-reg-
ulation of PP2A increases p-tau (Chen et al., 1992; Qian et al.,
2010; Martin et al., 2013). Reduced PP2A activity has been
reported post-mortem in patients with AD (Gong et al., 1995; Son-
tag et al., 2004), where phosphorylated PP2A is found in tangle-
bearing neurons (Liu et al., 2008). PP2A is sensitive to hypoxia and
its reduction is suggested to be a responsible factor for phosphoryla-
tion of tau leading to neuronal death (Koh, 2011).
Tau dephosphorylation was reported following ischaemia. Tau
can rephosphorylate at Ser396 during reperfusion while Ser262/Ser356
remains dephosphorylated (Shackelford & Yeh, 1998; Mailliot
et al., 2000). Ser262 is an insensitive residue to GSK-3b (Guerra-
Araiza et al., 2007), which implies the involvement of other kinases
in this scenario.
AMPK, the master controller of cellular metabolism and energy
status affects tau phosphorylation at many residues such as Ser369, 262
(Trinczek et al., 2004), however the extent of its role in changing
p-tau status in response to ischaemia has not been examined (Bright
et al., 2008). In this study, we used a cardiac arrest/reperfusion model
to evaluate the role of AMPK, GSK-3b and PP2A in time-
dependent phosphorylation of tau at Ser396, 262, (AMPK-dependent),
and Ser202/Thr205 (AMPK-independent, GSK-3b-dependent). We
tested the involvement of AMPK, GSK-3b and PP2A in regulating
p-tau by assessing the phosphorylation of GSK-3b at (Ser9), phospho-
rylation of PP2A (Tyr307) and phosphorylation of AMPK (Thr172).
Catalase, a downstream substrate of AMPK was also assessed during




The animal experiments in this study were approved by the Animal
Ethic Committee of Flinders University of South Australia and were
completed in accordance with the South Australian Prevention of
Cruelty to Animals Act 1985 and followed the Australian Code of
Practice for the Care and Use of Animals for Scientiﬁc Purposes,
2004.
Animal preparation
Sprague–Dawley rats were supplied by Laboratory Animal Services
of the University of Adelaide. The rats were kept in the Flinders
University Animal Facility until they reached the minimum age of
3 months. Female adult rats with the body weight of 250–350 g
and 3 months of age were used in this study. The animals had free
access to food and water. Twelve hours before the experiment the
rats were fasted with free access to water. The experimental time
point has been shown in Fig. 1. On the day of the experiment,
anesthesia was initiated by intraperitoneal injection of Ketamine
(Sigma, 343099) and Xylazine (Sigma, X1251), 100 mg/kg and
10 mg/kg body weight, respectively. The tail vein was cannulated
using a 22G 0.90 mm intravenous catheter for drug delivery. The
chest was shaved to provide a clear area for deﬁbrillator electrodes’
attachment and the electrocardiogram was recorded constantly via
chest leads using a deﬁbrillator/monitor (Philips HeartStart MRX;
Philips Healthcare Inc., USA). Oxygen saturation and pulse rate
were monitored constantly and recorded every 5 min via a Pulse-
oximeter attached to the animal’s paw. Ventilation was performed
via endotracheal intubation, using a 16-gauge cannula inserted in
the trachea and connected to a speciﬁc volume-controlled small ani-
mal ventilator with supplemental oxygen at 70 bpm and tidal vol-
ume adjusted to 6 mL/kg. Cardiac arrest (CA) was achieved, using
two phases of transoesophageal alternating current (AC) (with modi-
ﬁcations to the previous method used by Chen, et al. (Chen et al.,
2007). A pacing catheter (5F) with two end ring electrodes and a
0.5 cm gap was inserted into the oesophagus to a depth of 6–
6.5 cm and connected to a current generator ensuring that the cur-
rent was applied close to the heart without generating irreversible
respiratory muscle paralysis. Two phase electrical stimulation using
AC current consisting of 50 Hz AC 24V (phase 1), followed by
50 Hz AC 18V (phase 2) in order to generate the least oesophageal
thermal injury. Ventilation was stopped during the period of CA.
CA was conﬁrmed through the electrocardiogram monitor, showing
high voltage AC current and a loss of pulse detected by the oxime-
ter within a few seconds after applying the current. Different dura-
tions of CA (2, 4 and 8 min) were studied followed by CPR (60,
70, 90, 120 min: short-term recovery; 4w: long-term recovery). At
the end of the CA, if the heart rhythm was ventricular ﬁbrillation
(VF), the rats were deﬁbrillated via external electrodes connected to
a deﬁbrillator (Philips HeartStart MRx), using 8 Joules of current.
Standard CPR was performed supported by intravenous injection of
adrenaline (0.01–0.03 mg/kg) via the tail vein with manual cardiac
compressions at a rate of approximately 200–250/min. Compression
depth was about 30% the anterio-posterior chest diameter. Effective
circulation was conﬁrmed by a pulse oximeter reading that relies on
a pulse through a capillary bed to read oxygen saturation. Ventila-
tion was started immediately and performed using a volume-con-
trolled small animal ventilator with supplemental oxygen at 70
breaths per minute and tidal volume adjusted to 6 mL/kg. Restora-
tion of circulation under resuscitation was deﬁned as a CPR pulse
or natural pulse with a mean oxygen saturation of 85–95% or
greater during the time of resuscitation after CA. The animals were
monitored for the time of resuscitation of 60, 70, 90, 120 min
(short-term recovery) and 4 weeks (long-term recovery). For short-
term recovery groups, the pulse rate and oxygen saturation were
Fig. 1. Experimental time point of the study including the cardiac arrest (CA), reperfusion and recovery periods, brain perfusion and separation, protein assess-
ment and Western blot, and immuno-staining.
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monitored constantly and were recorded every 5 min. The animals
in the long-term recovery group were also constantly monitored
every 5 min until the achievement of a satisfactory cardiac output
(conﬁrmed via monitoring the heart rate and oxygen saturation) and
a normal conscious state. The animals were then returned to their
cages (one rat in each cage) and were returned to the animal house.
Post-resuscitation, the rats were supervised continuously until physi-
ological stability is demonstrated. The room temperature was set at
22 °C. Corneal lubricant application was administered during the
recovery period until spontaneous blinking was resumed. In the
post-resuscitation phase observation of the physiological parameters
such as capillary reﬁll time, body weight, physical appearance and
movement were assessed twice a day for 4 weeks. To obtain brain
samples at the end of recovery period (short and long-term), under
general anesthesia and the brains were perfused with cold Phosphate
Buffered Saline (PBS) the animals were killed painlessly and the
brains collected for the further analysis. The specimens were
divided into two with half being frozen in liquid nitrogen immedi-
ately after isolation and kept in 80 °C freezer. The remaining half
was ﬁxed in 10% paraformaldehyde for 48 h and subsequently pre-
pared in parafﬁn blocks, which were sectioned using a microtome
at 5 lm thickness. The sections were placed on Poly-d-Lysine
coated slides, deparafﬁnized in xylene, and hydrated in a graded
series of Ethanol.
Antibodies
Phosphorylated tau rabbit polyclonal antibody (Ser396; sc-101815,
Ser262 sc-101813), p-GSK-3b goat polyclonal antibody (Ser9;
sc-11757), p-PP2A-Ca/b mouse monoclonal antibody (F-8;
sc-271903), tau mouse monoclonal antibody (A-10; sc-390476),
GSK-3b rabbit polyclonal antibody (H-76; sc-9166) and PP2A-Aa
goat polyclonal antibody (C-20; sc-6112) were purchased from
Santa Cruz. Mouse monoclonal GFAP and Phospho-PHF-tau
pSer202/Thr205 Antibody (AT8) were obtained from Associate
Professor John Power from the Alzheimer’s and Parkinson’s
laboratory of Flinders University. The p-AMPK rabbit polyclonal
antibody (Thr172, #2531) and AMPK rabbit polyclonal antibody
(#2532) were purchased from Cell Signalling Australia. Catalase
sheep afﬁnity puriﬁed antibody was purchased from the
Proteomics Facility of Flinders University. Mouse NeuN antibody
(MAB377) was purchased from Merck Millipore Australia. Sec-
ondary antibodies were purchase from Jackson Immuno Research,
USA (HRP donkey anti-mouse, anti-rabbit, anti-goat, Biotinylated
donkey anti-rabbit, Alexa Fluor 488 Donkey anti-rabbit, Alexa
Fluor CY3 Donkey anti-mouse and Alexa Fluor CY3 Donkey
anti-Sheep).
Brain homogenate
The middle 1/3 (0.3–0.35 g) of the frozen brain containing parietal
cortex and hippocampus was homogenized in homogenizing extrac-
tion buffer containing protease inhibitors of Pepstatin A (Sigma,
P5318, 1 lg/mL) and Leupeptin (Sigma, L2884, 1 lg/mL). The
homogenate was centrifuged at 1000 g for 5 min at 4 °C and the
supernatants were stored at 80 °C until analysed.
Protein quantiﬁcation
The amount of total protein in each sample was calculated, using an
EZQ assay following the approved protocol (BioRad, Hercules, CA,
USA). Brieﬂy, 10 lL of smaple, 25 lL of four times sample buffer
(100% glycerol, 1M Tris/HCl pH 6.8, SDS, beta-mercaptoethanol,
H2O) and 65 25 lL H2O were mixed. A quantity of 10 lL of this
solution was added to 90 lL of H2O, thereafter 1 lL of each sam-
ple and the standard solution (serial dilutions of ovalbumin) were
loaded on to the assay paper in triplicate each in 96-well plates and
absorbance was measured, using an Image Master VDS-CL (Amer-
sham Biosciences) and quatiﬁed by CareStream molecular imaging
software.
Western blot analysis
To analyse electrophoretic mobility of p-tau, tau, p-GSK-3b, GSK-
3b, p-PP2A, PP2A, p-AMPK and AMPK, 30 lg of each sample in
the sample buffer was loaded to each well of Any kDTM TGX Stain-
free gel (Bio-Rad; 569033), along with 1 well of 5 lL Precision
Plus ProteinTM Dual Color Standards (Biorad). The current (100V,
300 mA) was applied to the gel for 20 min, to separate the proteins
based on their molecular weights. After standard SDS-PAGE separa-
tion, the proteins were transferred onto Polyvinylidene Diﬂuoride
(PVDF) membrane at 100 V for 30 min. After electroblotting, the
membranes were blocked for 1 hour at room temperature in a solu-
tion of 5% non-fat dry milk in Tris-buffered saline containing 0.1%
Tween 20 (pH 7.6). The separate membranes were incubated over-
night at 4 °C with primary antibodies of rabbit p-tau polyclonal
antibody at Ser396 (1:250), rabbit anti-p-tau (Ser262, 1:250), mouse
Phospho-PHF-tau (Ser202/Thr205, 1:1000), p-GSK-3b polyclonal
antibody at Ser9 (1:500), p-PP2A-Ca/b monoclonal antibody
(1:500), tau monoclonal antibody (1:250), GSK-3b polyclonal anti-
body (1:500), PP2A-Aa polyclonal antibody (1:500), p-AMPK poly-
clonal antibody (1:1000), AMPK polyclonal antibody (1:1000) and
sheep afﬁnity puriﬁed anti-catalase (1:300). On the following day,
the membranes were incubated for 1 hour at room temperature with
the HRP secondary antibodies (donkey anti- mouse, 1:3000; donkey
anti-rabbit, 1:3000, donkey anti-goat, 1:10 000). The blots were then
developed using an ECL and the chemiluminescence signal detec-
tion was performed using Fuji LAS4000 imager and quatiﬁed by
CareStream molecular imaging software, and were corrected by
actin levels.
Immunohistochemistry
DAB-metal-enhanced immunohistochemistry and Immunoﬂuores-
cence staining were undertaken by incubating 5lm brain sections of
parietal cortex and hippocampus with rabbit anti-phosphorylated tau
(Ser396, 1:250), or rabbit anti-phosphorylated (AMPK (Thr172,
1:250) for 18 h at 4o C to detect the phosphorylated tau and active
form of AMPK through DAB immunohistochemistry and
immunoﬂuorescence staining, respectively. The sections were subse-
quently incubated for 1 h at room temperature with the secondary
antibodies of Biotinylated donkey anti-rabbit for p-tau (1:1000,
Jackson) and Goat anti-rabbit (Alexa Flour 488, 1:500). The ﬂuores-
cent staining was visualized using a Leica SP5 5-channel laser scan-
ning confocal microscope from Flinders University Microscopy
Facility.
Statistical analysis
All of the data in this study were analysed using IBM SPSS Statis-
tics version of SPSS Software and are expressed as the mean  SD.
One-way ANOVAs was used to assess the differences between the
means of the groups followed by post hoc Tukey’s. Signiﬁcance
was deﬁned as P < 0.05.
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Results
ECG pattern at the termination of current
Cardiac arrest produced VF in 3 rats. Eight min CA was associated
with an asystolic rhythm when the AC current was terminated. In
the rest of the animals, AC current generated normal sinus rhythm
or sinus bradycardia (Fig. 2). Resuscitation involved deﬁbrillation,
CPR, mechanical ventilation, manual compression and IV adrenaline
injections, attaining an average SPO2 of 85  5% and an average
generated or natural pulse of 200  40/min (Table 1).
Effect of global ischaemia and different periods of reperfusion
on p-tau [(Ser396, 262, Ser202/Thr205 (AT8))]
Western blot analyses were carried out using parietal cortical and
subcortical hippocampus homogenates to investigate the levels of p-
tau and total tau protein in ischaemic groups vs. control group
(anaesthesia only) and in ischaemic/reperfusion groups relative to
control group. The level of tau phosphorylation at Ser396 was
reduced (One Way ANOVA, followed by TUKEY HSD,
F4,20 = 14.53, *P < 0.001 in 2 min ischaemia, 2 and 8 min ischae-
mia followed by 120 min reperfusion and 4 min ischaemia followed
by 60 min reperfusion vs. control). It was also reduced signiﬁcantly
in 2 min ischaemia followed by 60, 70 and 90 min reperfusion
(One Way ANOVA, followed by TUKEY HSD, F3,16 = 26.11,
*P < 0.001), whilst b-actin levels reﬂected equal loading across all
lanes (Fig. 3). Tau showed some rephosphorylation after 4 weeks
recovery. The difference between this group and control group as
well as the short-term reperfusion groups was not statistically signif-
icant, however, p-tau distribution after 4 weeks recovery was mainly
within the soma which in control groups showed the soma as well
as neurites’ distribution (Fig. 4B). The level of tau phosphorylation
at Ser262, the other residue which is phosphorylated by p-AMPK,
was also reduced after short periods of ischaemia (one-way ANOVA,
followed by TUKEY HSD, F5,24 = 26.54, *P < 0.001 in 2 min
ischaemia, and 2 min ischaemia followed by 60, 70, 90, and
120 min reperfusion vs. control). The phosphorylation of Ser202/
Thr205, the sites that are not phosphorylated by p-AMPK did not
show any signiﬁcant changes (one-way ANOVA, F8,36 = 0.42,
P = 0.90132, non-signiﬁcant).
To examine any underlying changes in tau protein, we evaluated
the level of total tau in the brain samples of the ischaemic group
and the groups with different periods of ischaemia and reperfusion.
The global ischaemia and reperfusion did not affect the tau protein
Fig. 2. (A) 4 min of high frequency AC generated the ventricular ﬁbrillation. (B) Normal sinus rhythm after 2 min of CA, while the rat stayed alive for 2 h.
(C) Sinus bradycardia after 2 min CA, and (D) Asystole after 8 min CA of 2 phases of high frequency AC.
Table 1. Two main physiological parameters of heart rate and oxygen satu-
ration that were recorded by Pulse-oximeter and chest leads using a deﬁbril-














Control 320  30 100–5 320  20 100–2
CA 320  30 100–5 200  40 85  10
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Fig. 3. (A) Tau phosphorylation at Ser396 and Ser262 and Ser202 /Thr205 after 2, 4 and 8 min ischaemia followed by 60, 70, 90 and 120 min reperfusion and
4 weeks recovery. Total amount of Tau is shown in all experimental groups. I-2’: 2 min ischaemia, 2’/60’: 2 min ischaemia followed by 60 min reperfusion, 2’/
70’: 2 min ischaemia followed by 70 min reperfusion, 2’/90’: 2 min ischaemia followed by 90 min reperfusion, 2’/120’: 2 min ischaemia followed by 120 min
reperfusion, 4’/60’: 4 min ischaemia followed by 60 min reperfusion, 8’/120’: 8 min ischaemia followed by 120 min reperfusion, 2’/4 w: 2 min ischaemia fol-
lowed by 4 weeks recovery period. *P < 0.001 all groups vs. control (One Way ANOVA). Error bars depict the SD. All values are expressed as percent change rela-
tive to control group and were corrected by the Actin level. (B) Immunohistochemistry staining of tau from cortex and hippocampus of control group (a, b) 2 min
ischaemia followed by 120 min of reperfusion and (c) long-term survivals of CA after 4 weeks of recovery following 2 min of CA. Scale bars, 100 lm.
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expression as no signiﬁcant change in total tau between different
ischaemia/reperfusion groups and between the ischaemia/reperfusion
groups and the control group was observed (one-way ANOVA,
F8,36 = 1.43, P = 0.21776, non-signiﬁcant) (Fig. 3).
GSK-3b activity during global ischaemia/reperfusion
We examined the level of phosphorylated GSK-3b (p-GSK-3b) at
Ser9 (inactive form) and the un-phosphorylated GSK-3b (active
form) to study the role of this enzyme in the early state of tau phos-
phorylation. There was no signiﬁcant change in p-GSK-3b between
the control and ischaemic groups (one-way ANOVA, F1,8 = 0.69,
P = 0.43025, nonsigniﬁcant). During reperfusion of 60, 70, 90,
120 min and 4 weeks, following 2, 4 and 8 min ischaemia, p-GSK-
3b remained unchanged (one-way ANOVA, F7,33 = 0.57,
P = 0.77478, nonsigniﬁcant). The total GSK-3b was also unchanged
between the groups (one-way ANOVA, F8,36 = 0.25, P = 0.97764,
non-signiﬁcant) (Fig. 4), indicating that the activity of GSK-3b was
constant, suggesting another mechanism rather than GSK-3b was
involved in tau dephosphorylation during ischaemia and reperfusion.
PP2A activity during global ischaemia/reperfusion
PP2A levels were assessed to investigate the role of this main tau
phosphatase in tau phosphorylation patterns after early ischaemia
and during reperfusion. Phosphorylated PP2A (p-PP2A) at Tyr307
(inactive form) did not show any signiﬁcant change (one-way
ANOVA, F8,36 = 2.11, P = 0.06043, no signiﬁcant difference between
all groups vs. control). PP2A (active form) remained at the same
levels with no signiﬁcant change between different times of ischae-
mia (2, 4 and 8 min) followed by 60, 70, 90, 120 min and 4 weeks
of reperfusion (One Way ANOVA, F8,36 = 1.98, P = 0.07757, non-
signiﬁcant) (Fig. 5). This suggests that tau dephosphorylation
occurred immediately after ischaemia and in the early reperfusion
times was independent of PP2A activity.
AMPK phosphorylation in ischaemia and reperfusion
The level of p-AMPK (active form) phosphorylated at Thr172 signiﬁ-
cantly decreased during ischaemia (2 and 4 min) followed by 60,
70, 90 and 120 min reperfusion (one-way ANOVA, followed by
TUKEY HSD, F4,20 = 6.8, P = 0.00126, *P < 0.005, 2 min ischae-
mia and 2 min ischaemia followed by 60, 70 and 90 min reperfu-
sion vs. control; One Way ANOVA, followed by TUKEY HSD,
F2,12 = 121.41, *P < 0.001, 2 min ischaemia followed by 120 min
reperfusion and 4 min ischaemia followed by 60 min reperfusion
vs. control) with almost the same pattern as p-tau. AMPK phospho-
rylation was increased in the 8 min CA group and after 4 weeks
recovery compare with the control group (one-way ANOVA, followed
by TUKEY HSD, F = 13.86, *P < 0.001), whilst b-actin levels
reﬂected equal loading across all lanes (Fig. 6A). The ischaemia and
reperfusion did not affect the AMPK protein expression as the total
AMPK remained unchanged during ischaemia/reperfusion (One
Way ANOVA, F8,36 = 0.12, P = 0.99808, no signiﬁcant difference
between all groups vs. each other and vs. control) (Fig. 6A).
Immunoﬂuorescent results showed AMPK activation in control
groups as well as positive staining for p-AMPK after 4 weeks of
recovery, which was mostly detected in neurons rather than glial
Fig. 4. Western blot analysis of the brain samples have been performed for p-GSK-3b at Ser9 and total protein of GSK-3b assessment from control group and
during early ischaemia/reperfusion and after 4 weeks of recovery. All values are expressed as percent change relative to control group and were corrected by
the Actin level. I-2’: 2 min ischaemia, 2’/60’: 2 min ischaemia followed by 60 min reperfusion, 2’/70’: 2 min ischaemia followed by 70 min reperfusion, 2’/
90’: 2 min ischaemia followed by 90 min reperfusion, 2’/120’: 2 min ischaemia followed by 120 min reperfusion, 4’/60’: 4 min ischaemia followed by 60 min
reperfusion, 8’/120’: 8 min ischaemia followed by 120 min reperfusion, 2’/4 w: 2 min ischaemia followed by 4 weeks recovery period. Error bars depict the
SD. All values are expressed as percent change relative to control group and were corrected by the Actin level.
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cells, however a positive AMPK activation was missing in the early
response to ischaemia/reperfusion (Fig. 6B). Changes in p-tau in
response to ischaemia compared with control groups follows the
same pattern of p-AMPK alteration within the same periods of
ischaemia/reperfusion, which suggests another evidence for AMPK
kinase activity on tau following ischaemia, when the level and activ-
ity of GSK-3b and PP2A have not been change.
Effect of ischaemia and reperfusion on catalase, the
downstream substrate of AMPK
One of the known upstream regulators of catalase is AMPK. We
examined the effect of ischaemia on catalase levels in the different
groups by Western blot. Catalase reduced following 2 min ischae-
mia (one-way ANOVA, followed by TUKEY HSD, F1,8 = 98.75,
*P < 0.001) and also in ischaemia and reperfusion groups versus
control group (one-way ANOVA, followed by TUKEY HSD,
F7,32 = 546.21, *P < 0.001) (Fig. 6A). AMPK activation in
hypoxic situations is known to increase the cellular level of catalase
(Sengupta et al., 2011; Awad et al., 2014). A lower level of catalase
after short periods of ischaemia is consistent with the lower levels
of AMPK activation that we have observed.
Discussion
This study, revealed an almost instant dephosphorylation of tau pro-
tein as one of the ﬁrst events following a global ischaemia in the
brain, in two residues of Ser396 and Ser262, the latest one is speciﬁ-
cally affected by kinase activity of AMPK. Our CA model of global
cerebral ischaemia in the rat provided us with a similar situation to
CA in human beings, which could be followed by reperfusion due
to cardiopulmonary resuscitation. Our results are inconsistent with a
previous study, showing the tau dephosphorylation in a transient
ischaemic model of stroke (Shackelford & Yeh, 1998). Song et al.
(Song et al., 2013) reported that dephosphorylated tau after 15 min
of ischaemia had been rephosphorylated during reperfusion, however
in our study, shorter periods of ischaemia (up to 8 min) caused tau
dephosphorylation at Ser396 which had not shown rephosphorylation
within a reperfusion time of 60, 70, 90 and 120 min. This suggests
that shorter ischaemic periods possibly cause dephosphorylation
through a different mechanism to that involved in phosphorylation
control after longer ischaemic times.
The leading cause of changes in the neuronal status of tau
between phosphorylated, hyperphosphorylated and dephosphorylated
forms has been known as a deregulated activity of tau protein
kinases and phosphatases, with a documented role in AD pathology
(Liu et al., 2005a; Qian et al., 2010). The main tau kinase is GSK;
its GSK-3b isoform can phosphorylate tau at multiple sites,
including Ser235, Ser396, Ser202/Thr205, Thr175 and Thr181 (Taka-
shima, 2006; Hanger et al., 2009; Hernandez et al., 2013), but not
at Ser262 (Guerra-Araiza et al., 2007) Animal in vivo studies have
also shown that activation or over-expression of GSK-3b affects
microtubule assembly leading to their disruption due to tau
hyperphosphorylation (Lucas et al., 2001; Hernandez et al., 2013).
Human post-mortem results from AD brains have reported the
co-existence of activated GSK-3b with NFTs in dystrophic neurites
and astrocytes (Ferrer et al., 2002). Tau phosphorylation at Ser262 is
one of the principal causes for loss of tau’s physiological ability to
attach to microtubules, which is mediated by AMPK rather than
GSK-3b (Iijima et al., 2010). Among the many different phos-
phatases, PP2A is the dominant phosphatase responsible for 70% of
tau dephosphorylation, its inhibited activity has been suggested as
Fig. 5. Western blot analysis of the brain samples have been performed for PP2A and p-PP2A assessment from control group and during ischaemia and reper-
fusion and after 4 weeks of recovery. I-2’: 2 min ischaemia, 2’/60’: 2 min ischaemia followed by 60 min reperfusion, 2’/70’: 2 min ischaemia followed by
70 min reperfusion, 2’/90’: 2 min ischaemia followed by 90 min reperfusion, 2’/120’: 2 min ischaemia followed by 120 min reperfusion, 4’/60’: 4 min ischae-
mia followed by 60 min reperfusion, 8’/120’: 8 min ischaemia followed by 120 min reperfusion, 2’/4 w: 2 min ischaemia followed by 4 weeks recovery period.
Error bars depict the SD. All values are expressed as percent change relative to control group and were corrected by the Actin level.
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Fig. 6. (A) Western blot of protein levels of p-AMPK, AMPK and catalase have been analysed using the brain samples from control group and during ischae-
mia and reperfusion and after 4 weeks of recovery. I-2’: 2 min ischaemia, 2’/60’: 2 min ischaemia followed by 60 min reperfusion, 2’/70’: 2 min ischaemia fol-
lowed by 70 min reperfusion, 2’/90’: 2 min ischaemia followed by 90 min reperfusion, 2’/120’: 2 min ischaemia followed by 120 min reperfusion, 4’/60’:
4 min ischaemia followed by 60 min reperfusion, 8’/120’: 8 min ischaemia followed by 120 min reperfusion, 2’/4 w: 2 min ischaemia followed by 4 weeks
recovery period. *P < 0.005 for p-AMPK in I-2’, 2’/60’, 2’/70’ and 2’/90’ vs. control, *P < 0.001, for p-AMPK in 2’/120’ and 4’/60’ versus control, also for
8’/120’ and 2’/4 w versus control (one-way ANOVA). For catalase, *P < 0.001 for all experimental groups versus control group (one-way ANOVA). Error bars
depict the SD. All values are expressed as percent change relative to control group and were corrected by the Actin level. (B) Evaluating the of AMPK activity
through analysing p-AMPK (green) presence and distribution within the neurons that were co-stained with NeuN (Red, a–c) or GFAP (Red, d–f) from the pari-
etal cortex and hippocampus of control, 2 min isachemia followed by 2 h reperfusion or 4 weeks recovery groups.
© 2016 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
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an underlying mechanism for tau hyperphosphorylation in AD (Liu
et al., 2005a; Rudrabhatla & Pant, 2011). To investigate the role of
tau kinase-phosphatase balance break down in creating the early pat-
tern of tau dephophorylation, which persisted during reperfusion, we
examined the level of GSK-3b and PP2A activities. Our hypothesis
was based on GSK-3b inactivation in early ischaemia and reperfu-
sion. Our observations however showed no obvious change in phos-
phorylated GSK-3b at Ser9 (inactive form) and the total GSK-3b
within very short periods of ischaemia (2–8 min) as well as reperfu-
sion (60, 70, 90 and 120 min). Additionally, both PP2A (active
form) and p-PP2A at Tyr307 (inactive form) remained at an almost
constant level.
We suggest that that changes in GSK-3b and PP2A activities on
tau protein are not the initial mechanism of reducing tau phosphory-
lation in the very early stages of ischaemia. The unchanged phos-
phorylation status of Ser202/Thr205, residues that are directly affected
by GSK-3b activity supports our hypothesis. Theoretically, the
dephosphorylation of tau could be due to an up-regulation or down-
regulation of tau kinases and phosphatases, respectively. PP2A has
been proposed as the major tau phosphatase, it has been shown that
tau phosphorylation is not always affected by its activity (Gong
et al., 2000; Kins et al., 2001), suggesting a role for other phos-
phatases such as Protein Phosphatase 5 in addition to PP2A (Liu
et al., 2005b). On the other hand, tau could be phosphorylated/hy-
perphosphorylated at more than 40 sites of Ser/Thr residues (Hanger
et al., 2007), by other kinases such as calmodulin-dependent protein
kinase (CAMK) (Iijima-Ando et al., 2010; Thornton et al., 2011),
the AGC kinase subfamily (including PKA and PKC) (Pei et al.,
2006; Virdee et al., 2007), and AMP-activated protein kinase
(AMPK)-related kinase (Mailliot et al., 2000; Thornton et al., 2011;
Yoshida & Goedert, 2012).
Previous studies have reported an increased in p-AMPK in a rat
model of middle cerebral artery occlusion MCAO for 2 h, starting
after 90 min of ischaemia (McCullough et al., 2005). Our results
showed a very early dephosphorylation of AMPK starting as early
as two minutes after onset of ischaemia, which did not show rephos-
phorylation during reperfusion times of 60, 70, 90 and 120 min.
The global decrease in p-AMPK levels within the ﬁrst minutes of
ischaemia suggested that AMPK activation reported after longer
periods of ischaemia does not occur in the immediate stage of
ischaemia. We submit that this reduced AMPK activation could be
considered as the ﬁrst mechanism of neuronal protection against
ischaemic insult. A previous study showed a neuro-protective effect
of AMPK inhibition in stroke that supports our hypothesis (Li et al.,
2007). After 8 min of ischaemia p-AMPK levels began to rise and
remained at a very high level in the long-term recovery group after
4 weeks. This second stage of AMPK phosphorylation is consistent
with the role of AMPK in modulating energy metabolism of cells
triggered by hypoxia/anoxia, adjusting the intracellular ATP by stim-
ulating the catabolic process producing ATP, and blocking the ana-
bolic process consuming ATP (Culmsee et al., 2001; Russell et al.,
2004; Ramamurthy & Ronnett, 2006). Tau phosphorylation is also
an indicator of altered neuronal metabolism (van der Harg et al.,
2014). Thus, a number of metabolic-related events of ischaemia
could explain tau dephosphorylation, with the short-term and hyper-
phosphorylation during the long-term recovery.
We found that the level of p-AMPK was reduced within the ﬁrst
min of ischaemia and remained reduced during the reperfusion
time, with the same pattern of reduction in p-tau. Further evidence
to support the AMPK activity alteration immediately after ischae-
mia, and during reperfusion comes from the results of testing one
of the other main downstream substances of AMPK, which is
catalase. There are several schools of thought, showing a direct
link between activation of AMPK during hypoxia and increasing
the level of cellular catalase (Awad et al., 2014). Sengupta et al.
(Sengupta et al., 2011) found that hypoxia/reperfusion increased
the cardiomyocytes catalase through activation of AMPK. Our data
showed that the catalase level reduced signiﬁcantly immediately
after ischaemia and during reperfusion in parallel with a reduction
in AMPK activity. These ﬁndings support our hypothesis of the
involvement of the AMPK pathway in early tau dephosphorylation,
suggesting the dominant role for this kinase in changing tau phos-
phorylation status as one of the immediate brain response to
ischaemic situations.
Further examination of the long-term effect of ischaemia after
4 weeks recovery showed rephosphorylation of AMPK in parallel
with tau hyperphosphorylation. This effect could be consistent with
the hypothesis that AMPK activation is an important component of
cell adaptive mechanisms to ischaemic insult protecting cells in
response to a persistent stressful situation (Russell et al., 2004).
Considering AMPK as one of the kinases responsible for the phos-
phorylation of tau (Thornton et al., 2011; Yoshida & Goedert,
2012), we showed the pattern of tau phosphorylation following short
episodes of ischaemia was similar to that of p-AMPK, without dra-
matic changes in GSK-3b and/or PP2A activity during short-term
and long-term recovery. This suggests a possible role for AMPK
either as the main sensor of cellular energy balance taking the lead-
ing role in deﬁning the phosphorylation status of tau or closely
linked to that sensor. We believe that the global situation of reduced
oxygen supply leads to a very early decrease in phosphorylation of
AMPK, with a consequent reduction in p-tau. This reduced phos-
phorylation of two main proteins could be a possible cellular mecha-
nism saving energy for more essential cellular functions.
In conclusion, this study suggests an early mechanism for
dephosphorylation of the tau protein during global cerebral ischae-
mia/reperfusion linked to reduced AMPK activity. While GSK-3b
and PP2A, the usual tau kinase and phosphatase, are considered to
have central roles in phosphorylation/dephosphorylation of tau in
the longer term response to brain ischaemia (Song et al., 2013), we
suggest AMPK as either the most likely sensor of metabolic stress
in the very early stages of ischemia or closely linked to that sen-
sor. In the early stages of ischemia reduction in AMPK activity
plays a dominant role in reducing tau phosphorylation, with the
possible beneﬁt of saving more ATP for neuronal survival until
energy production can be restored. This proposed neuroprotective
event seems to be temporary and the full activation of AMPK at
later stages of ischaemia eventually takes place, switching on the
entire ATP catabolic pathways while switching off the ATP-con-
suming anabolic ones.
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